Temat: "Quinazolines" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations.
Autorzy:: Malarz K; Institute of Physics, University of Silesia in Katowice, Chorzów, Poland.
Mularski J; Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
Pacholczyk M; Department of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
Musiol R; Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2201410.
Typ publikacji:: Journal Article
MeSH Terms:: Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/chemistry
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/chemistry
Molecular Docking Simulation ; Quinazolines/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.
Autorzy:: Abdallah AE; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Mabrouk RR; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Al Ward MMS; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Eissa SI; Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
Elkaeed EB; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
Mehany ABM; Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Abo-Saif MA; Biochemistry Department, Faculty of Pharmacy, Tanta university, Tanta, Egypt.
El-Feky OA; Biochemistry Department, Faculty of Pharmacy, Tanta university, Tanta, Egypt.
Alesawy MS; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
El-Zahabi MA; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 573-591.
Typ publikacji:: Journal Article
MeSH Terms:: Molecular Docking Simulation*
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Protein Kinase Inhibitors/*pharmacology
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Nitrobenzenes/chemical synthesis ; Nitrobenzenes/chemistry ; Nitrobenzenes/pharmacology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Quinazolines/pharmacology ; Quinoxalines/chemical synthesis ; Quinoxalines/chemistry ; Quinoxalines/pharmacology ; Structure-Activity Relationship ; Vascular Endothelial Growth Factor Receptor-2/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Autorzy:: Altamimi AS; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
El-Azab AS; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdelhamid SG; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
Alamri MA; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Bayoumi AH; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
Alqahtani SM; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Alabbas AB; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Altharawi AI; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Alossaimi MA; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Mohamed MA; Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Alkharj 11942, Saudi Arabia.; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2021 May 18; Vol. 26 (10). Date of Electronic Publication: 2021 May 18.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Screening Assays, Antitumor*
Molecular Docking Simulation*
Antineoplastic Agents/*pharmacology
ErbB Receptors/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*chemical synthesis
Quinazolines/*pharmacology
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors
Antineoplastic Agents/analysis ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Biological Assay ; Cell Line, Tumor ; ErbB Receptors/metabolism ; Humans ; Inhibitory Concentration 50 ; Molecular Dynamics Simulation ; Protein Kinase Inhibitors/analysis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/analysis ; Quinazolines/chemistry ; Vascular Endothelial Growth Factor Receptor-2/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR.
Autorzy:: Almalki FA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Shawky AM; Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia.; Central Laboratory for Micro-analysis, Minia University, Minia 61519, Egypt.
Abdalla AN; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.; Department of Pharmacology and Toxicology, Medicinal And Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan.
Gouda AM; Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2021 Oct 24; Vol. 26 (21). Date of Electronic Publication: 2021 Oct 24.
Typ publikacji:: Journal Article
MeSH Terms:: Molecular Docking Simulation*
Acrylamides/*pharmacology
Crown Ethers/*pharmacology
Indoles/*pharmacology
Piperazines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Quinazolines/*pharmacology
Acrylamides/chemistry ; Binding Sites/drug effects ; Crown Ethers/chemistry ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Indoles/chemistry ; Ligands ; Molecular Structure ; Piperazines/chemistry ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemistry ; Quinazolines/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Discovery of 5-methyl- N -(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors.
Autorzy:: Im D; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Moon H; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Kim J; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Oh Y; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Jang M; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.
Hah JM; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do, Korea.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2020 Dec; Vol. 35 (1), pp. 1110-1115.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Discovery*
Isoxazoles/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
Dose-Response Relationship, Drug ; Humans ; Isoxazoles/chemical synthesis ; Isoxazoles/chemistry ; Molecular Docking Simulation ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Structure-Activity Relationship ; fms-Like Tyrosine Kinase 3/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Autorzy:: Kim M; Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Yoon JH; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Ahn J; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jeon MJ; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim HK; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Lim DJ; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kang HC; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Kim IJ; Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Shong YK; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim TY; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim BH; Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.; Pokaż więcej
Źródło:: Endocrinology and metabolism (Seoul, Korea) [Endocrinol Metab (Seoul)] 2020 Sep; Vol. 35 (3), pp. 587-594. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Carcinoma, Neuroendocrine/*drug therapy
Piperidines/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Quinazolines/*therapeutic use
Thyroid Neoplasms/*drug therapy
Carcinoma, Neuroendocrine/mortality ; Carcinoma, Neuroendocrine/pathology ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Piperidines/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Quinazolines/adverse effects ; Republic of Korea ; Retrospective Studies ; Thyroid Neoplasms/mortality ; Thyroid Neoplasms/pathology
SCR Disease Name:: Thyroid cancer, medullary

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Autorzy:: Wang C; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Xu S; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Peng L; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Zhang B; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Zhang H; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Hu Y; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Zheng P; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.
Zhu W; a Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy , Jiangxi Science & Technology Normal University , Nanchang , Jiangxi , China.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2019 Dec; Vol. 34 (1), pp. 203-217.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Design*
Antineoplastic Agents/*pharmacology
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm/drug effects ; Drug Screening Assays, Antitumor ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Gefitinib/chemistry ; Gefitinib/pharmacology ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Molecular Docking Simulation ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Structure-Activity Relationship

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Novel 4-arylaminoquinazolines bearing N , N -diethyl(aminoethyl)amino moiety with antitumour activity as EGFR -TK inhibitor.
Autorzy:: Zhang Y; National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University , Xi'an , P. R. China.
Chen L; School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Li X; School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Gao L; School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Hao Y; School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Li B; National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University , Xi'an , P. R. China.; School of Chemistry & Chemical Engineering, Shaanxi Normal University , Xi'an , P. R. China.
Yan Y; National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, The Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry, The Ministry of Education, College of Life Sciences, Shaanxi Normal University , Xi'an , P. R. China.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2019 Dec; Vol. 34 (1), pp. 1668-1677.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; Cell Cycle/drug effects ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Autorzy:: Lei L; Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China.
Wang WX; Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China.
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, People's Republic of China.
Li JL; Department of Radiotherapy, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, People's Republic of China.
Fang Y; Department of Oncology, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, People's Republic of China.
Wang H; Department of Lung Cancer, The Fifth Medical Center, General of PLA, Beijing, People's Republic of China.
Zhuang W; Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Zhang YB; Department of Oncology, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
Wang LP; Department of Oncology, Baotou Cancer Hospital, Baotou, Inner Mongolia, People's Republic of China.
Fang MY; Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Wang XJ; Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China.
Lv TF; Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.
Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2020 Jan; Vol. 9 (1), pp. 12-18. Date of Electronic Publication: 2019 Nov 06.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung/*drug therapy
Crown Ethers/*pharmacology
Drug Resistance, Neoplasm/*genetics
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Aged ; Asian People/genetics ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; China/epidemiology ; Circulating Tumor DNA/blood ; Circulating Tumor DNA/genetics ; Crown Ethers/therapeutic use ; DNA Mutational Analysis ; Disease Progression ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Female ; Follow-Up Studies ; High-Throughput Nucleotide Sequencing ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation/drug effects ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/therapeutic use ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Autorzy:: Giordano A; Department of Medicine, Division of Hematology & Oncology, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Liu Y; Department of Medicine, Division of Hematology & Oncology, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Armeson K; Department of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Park Y; Department of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Ridinger M; Trovagene Oncology, San Diego, California, United States of America.
Erlander M; Trovagene Oncology, San Diego, California, United States of America.
Reuben J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Britten C; Department of Medicine, Division of Hematology & Oncology, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Kappler C; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
Yeh E; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indianapolis, United States of America.
Ethier S; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Nov 21; Vol. 14 (11), pp. e0224420. Date of Electronic Publication: 2019 Nov 21 (Print Publication: 2019).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Cell Cycle Proteins/*antagonists & inhibitors
Piperazines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Protein Serine-Threonine Kinases/*antagonists & inhibitors
Proto-Oncogene Proteins/*antagonists & inhibitors
Pyrazoles/*pharmacology
Quinazolines/*pharmacology
Triple Negative Breast Neoplasms/*drug therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzimidazoles/pharmacology ; Benzimidazoles/therapeutic use ; Cell Line, Tumor ; Docetaxel/pharmacology ; Docetaxel/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Drug Synergism ; Female ; Humans ; Mice ; Piperazines/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; Quinazolines/therapeutic use ; Thiophenes/pharmacology ; Thiophenes/therapeutic use ; Triple Negative Breast Neoplasms/pathology ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays ; Polo-Like Kinase 1

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Comparison of the ligand-binding properties of fluorescent VEGF-A isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET.
Autorzy:: Peach CJ; Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK.; Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, The Midlands, UK.
Kilpatrick LE; Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK.; Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, The Midlands, UK.
Woolard J; Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK.; Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, The Midlands, UK.
Hill SJ; Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK.; Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, The Midlands, UK.; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2019 Sep; Vol. 176 (17), pp. 3220-3235. Date of Electronic Publication: 2019 Jul 15.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Bioluminescence Resonance Energy Transfer Techniques*
Fluorescence*
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors
Binding Sites/drug effects ; Cell Membrane/drug effects ; Cell Membrane/metabolism ; Cells, Cultured ; Dose-Response Relationship, Drug ; Endosomes/drug effects ; Endosomes/metabolism ; HEK293 Cells ; Humans ; Ligands ; Protein Isoforms/drug effects ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemistry ; Structure-Activity Relationship ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor Receptor-2/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.
Autorzy:: Indra R; Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic.
Pompach P; Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic.
Martínek V; Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic.
Takácsová P; Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic.
Vavrová K; Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic.
Heger Z; Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-61300 Brno, Czech Republic.
Adam V; Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-61300 Brno, Czech Republic.
Eckschlager T; Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, CZ-150 06 Prague 5, Czech Republic.
Kopečková K; Department of Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol, V Uvalu 84/1, CZ-150 06 Prague 5, Czech Republic.
Arlt VM; Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, UK.; NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England and Imperial College London, 150 Stamford Street, London SE1 9NH, UK.
Stiborová M; Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic. .; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2019 Jul 10; Vol. 20 (14). Date of Electronic Publication: 2019 Jul 10.
Typ publikacji:: Journal Article
MeSH Terms:: Oxidation-Reduction*
Antineoplastic Agents/*pharmacology
Cytochrome P-450 CYP3A/*metabolism
Enzymes/*metabolism
Piperidines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Animals ; Antineoplastic Agents/chemistry ; Cytochrome P-450 CYP3A/chemistry ; Dose-Response Relationship, Drug ; Enzymes/chemistry ; Humans ; Mice ; Microsomes, Liver/metabolism ; Models, Molecular ; Molecular Conformation ; Molecular Structure ; Piperidines/chemistry ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemistry ; Rabbits ; Rats ; Recombinant Proteins

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
Autorzy:: Sankhe K; Department of Pharmaceutical Chemistry, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Prabhu A; Department of Pharmaceutical Chemistry and Quality Assurance, Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Khan T; Department of Pharmaceutical Chemistry and Quality Assurance, Bhanuben Nanavati College of Pharmacy, Mumbai, India.; Pokaż więcej
Źródło:: Chemical biology & drug design [Chem Biol Drug Des] 2021 Jul; Vol. 98 (1), pp. 73-93. Date of Electronic Publication: 2021 May 15.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Antineoplastic Agents/*chemistry
Aurora Kinase A/*antagonists & inhibitors
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*chemistry
Animals ; Antineoplastic Agents/pharmacology ; Azepines/chemistry ; Azepines/pharmacology ; Benzamides/chemistry ; Benzamides/pharmacology ; Drug Approval ; Drug Resistance ; Drug Screening Assays, Antitumor ; Flavones/chemistry ; Flavones/pharmacology ; Gene Expression Regulation ; Humans ; Indazoles/chemistry ; Indazoles/pharmacology ; Organophosphates/chemistry ; Organophosphates/pharmacology ; Protein Binding ; Protein Conformation ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/chemistry ; Pyrazoles/pharmacology ; Pyrimidines/chemistry ; Pyrimidines/pharmacology ; Quinazolines/chemistry ; Quinazolines/pharmacology ; Structure-Activity Relationship

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
Autorzy:: Ikeda Y; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Yasutake R; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Yuki R; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Saito Y; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Nakayama Y; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 May 27; Vol. 22 (11). Date of Electronic Publication: 2021 May 27.
Typ publikacji:: Journal Article
MeSH Terms:: Aurora Kinase B/*antagonists & inhibitors
Cell Survival/*drug effects
Cyclin B1/*metabolism
Imidazoles/*pharmacology
Mitosis/*drug effects
Protein Kinase Inhibitors/*pharmacology
Pyrazines/*pharmacology
Benzamides/pharmacology ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Proteolysis ; Quinazolines/pharmacology ; Receptor, IGF Type 1/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Autorzy:: Xin M; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Duan W; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Feng Y; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Hei YY; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Zhang H; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Shen Y; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Zhao HY; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Mao S; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Zhang SQ; a Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2018 Dec; Vol. 33 (1), pp. 651-656.
Typ publikacji:: Journal Article
MeSH Terms:: Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Piperidines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrrolidines/*pharmacology
Quinazolines/*pharmacology
Class I Phosphatidylinositol 3-Kinases/metabolism ; Dose-Response Relationship, Drug ; Humans ; Molecular Structure ; Piperidines/chemistry ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrrolidines/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Structure-Activity Relationship

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Autorzy:: Ghorab MM; a Department of Pharmacognosy, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.; b Department of Drug Radiation Research , National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority , Cairo , Egypt.
Alsaid MS; a Department of Pharmacognosy, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.
Soliman AM; b Department of Drug Radiation Research , National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority , Cairo , Egypt.
Al-Mishari AA; c Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy , King Saud University , Riyadh , Saudi Arabia.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2018 Dec; Vol. 33 (1), pp. 67-73.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*pharmacology
ErbB Receptors/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; ErbB Receptors/metabolism ; Humans ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinazolines/chemical synthesis ; Quinazolines/chemistry ; Structure-Activity Relationship

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor.
Autorzy:: Wang J; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Han Y; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shi X; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li Q; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang P; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan P; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ma F; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Luo Y; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cai R; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fan Y; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chen S; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li Q; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xu B; Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2018 Aug; Vol. 9 (8), pp. 1041-1047. Date of Electronic Publication: 2018 Jun 12.
Typ publikacji:: Clinical Trial, Phase I; Journal Article
MeSH Terms:: Breast Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Protein Kinase Inhibitors/*pharmacokinetics
Quinazolines/*administration & dosage
Quinazolines/*pharmacokinetics
Adult ; Breast Neoplasms/blood ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Maximum Tolerated Dose ; Middle Aged ; Protein Kinase Inhibitors/adverse effects ; Quinazolines/adverse effects ; Random Allocation ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization.
Autorzy:: Zayed MF; Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah 41477, Al-Munawarah, Saudi Arabia. .; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt. .
Rateb HS; Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah 41477, Al-Munawarah, Saudi Arabia. .; Department of Pharmaceutical and Medicinal Chemistry, Pharmacy College, Misr University for Science and Technology, Cairo 12568, Egypt. .
Ahmed S; Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah 41477, Al-Munawarah, Saudi Arabia. .; Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assuit 71526, Egypt. .
Khaled OA; Department of Physical Therapy, College of Medical Rehabilitation Sciences, Taibah University, Al-Madinah 41477, Al-Munawarah, Saudi Arabia. .; Department of Basic Science, Faculty of Physical Therapy, Cairo University, Cairo 12613, Egypt. .
Ibrahim SRM; Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah 41477, Al-Munawarah, Saudi Arabia. .; Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. .; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2018 Jul 12; Vol. 23 (7). Date of Electronic Publication: 2018 Jul 12.
Typ publikacji:: Journal Article
MeSH Terms:: ErbB Receptors*/antagonists & inhibitors
ErbB Receptors*/chemistry
ErbB Receptors*/metabolism
Molecular Docking Simulation*
Protein Kinase Inhibitors*/chemical synthesis
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Quinazolines*/chemical synthesis
Quinazolines*/chemistry
Quinazolines*/pharmacology
Tubulin*/chemistry
Tubulin*/metabolism
Tubulin Modulators*/chemical synthesis
Tubulin Modulators*/chemistry
Tubulin Modulators*/pharmacology
Humans ; MCF-7 Cells

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: EGFR inhibitor, AG1478, inhibits inflammatory infiltration and angiogenesis in mice with diabetic retinopathy.
Autorzy:: Ju X; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.; The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Yang X; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.; The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Yan T; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Chen H; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.; The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Song Z; The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Zhang Z; The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Wu W; The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Wang Y; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.; Pokaż więcej
Źródło:: Clinical and experimental pharmacology & physiology [Clin Exp Pharmacol Physiol] 2019 Jan; Vol. 46 (1), pp. 75-85. Date of Electronic Publication: 2018 Sep 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Diabetic Retinopathy/*pathology
Diabetic Retinopathy/*physiopathology
ErbB Receptors/*antagonists & inhibitors
Neovascularization, Pathologic/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Quinazolines/*pharmacology
Tyrphostins/*pharmacology
Animals ; Disease Progression ; Female ; Inflammation/pathology ; Macrophages/cytology ; Macrophages/drug effects ; Male ; Mice ; Mitochondria/drug effects ; Mitochondria/pathology ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/therapeutic use ; Retinal Vessels/drug effects ; Retinal Vessels/pathology ; Tyrphostins/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Autorzy:: Zhang Z; Cancer Center, Daping Hospital, Army Medical University, #10 Changjiang Zhilu, Daping, Yuzhong District, Chongqing, 400042, China.
Lian X; Department of Oncology, Jiangjin Strict Central Hospital, Chongqing, 402260, China.
Xie W; Cancer Center, Daping Hospital, Army Medical University, #10 Changjiang Zhilu, Daping, Yuzhong District, Chongqing, 400042, China.
Quan J; Department of Oncology, Jiangjin Strict Central Hospital, Chongqing, 402260, China.
Liao M; Cancer Center, Daping Hospital, Army Medical University, #10 Changjiang Zhilu, Daping, Yuzhong District, Chongqing, 400042, China.
Wu Y; Department of Oncology, Second Hospital Affiliated to Chongqing Medical University, #76 Linjiang Road, Chongqing, 40010, China.
Yang ZZ; Department of Oncology, Second Hospital Affiliated to Chongqing Medical University, #76 Linjiang Road, Chongqing, 40010, China. .
Wang G; Cancer Center, Daping Hospital, Army Medical University, #10 Changjiang Zhilu, Daping, Yuzhong District, Chongqing, 400042, China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Dec 01; Vol. 10 (1), pp. 20924. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Autophagy*/drug effects
Drug Resistance, Neoplasm*/drug effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*enzymology
Lung Neoplasms/*drug therapy
Poly (ADP-Ribose) Polymerase-1/*metabolism
Protein Kinase Inhibitors/*therapeutic use
Animals ; Autophagosomes/drug effects ; Autophagosomes/metabolism ; Autophagosomes/ultrastructure ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Crown Ethers/pharmacology ; Crown Ethers/therapeutic use ; Disease-Free Survival ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/pathology ; Mice, Nude ; Microtubule-Associated Proteins/metabolism ; Phthalazines/pharmacology ; Phthalazines/therapeutic use ; Piperazines/pharmacology ; Piperazines/therapeutic use ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; Sequestosome-1 Protein/metabolism ; Signal Transduction/drug effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Quinazolines"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język